pentobarbital decreases amounts of panobinostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Powerful CYP3A4 inducers can decrease panobinostat concentrations by ~70% and cause therapy failure.
Coadministration of zuranolone with other CNS depressants may well improve impairment of psychomotor general performance or CNS depressant results. If unavoidable, take into consideration dose reduction. .
pentobarbital will lower the extent or effect of propafenone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.
pentobarbital will minimize the level or outcome of eplerenone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Mysterious.
pentobarbital will minimize the level or outcome of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
pentobarbital will lower the extent or impact of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.
In case the dose of your concomitant CYP3A4 inducer can't be lessened or discontinued, implant removal could possibly be necessary along with the affected individual must then be handled with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inducer is discontinued in the individual who continues to be stabilized on buprenorphine, watch the patient for overmedication.
pentobarbital will reduce the extent or influence of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will decrease the level or influence of methadone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Warning when discontinuing CYP3A4 inducers that are coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone may well boost and can lead to likely lethal respiratory melancholy.
pentobarbital will lower the extent or effect of almotriptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Psychological, tolerance and Bodily dependence may arise with continued use; people with psychological dependence on barbiturates might build a physical dependence on barbiturates by raising or lowering the dosage interval with out consulting a health practitioner
pentobarbital will lower the extent or 戊巴比妥鈉製作 effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
sodium oxybate and pentobarbital each improve sedation. Stay away from or Use Alternate Drug. Restrict use to clients for whom option remedy alternatives are inadequate